1. Home
  2. ANAB vs ASIC Comparison

ANAB vs ASIC Comparison

Compare ANAB & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • ASIC
  • Stock Information
  • Founded
  • ANAB 2005
  • ASIC 2018
  • Country
  • ANAB United States
  • ASIC United States
  • Employees
  • ANAB N/A
  • ASIC N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • ASIC Property-Casualty Insurers
  • Sector
  • ANAB Health Care
  • ASIC Finance
  • Exchange
  • ANAB Nasdaq
  • ASIC Nasdaq
  • Market Cap
  • ANAB 1.0B
  • ASIC 1.1B
  • IPO Year
  • ANAB 2017
  • ASIC 2025
  • Fundamental
  • Price
  • ANAB $38.47
  • ASIC $18.20
  • Analyst Decision
  • ANAB Buy
  • ASIC Strong Buy
  • Analyst Count
  • ANAB 12
  • ASIC 4
  • Target Price
  • ANAB $63.30
  • ASIC $25.50
  • AVG Volume (30 Days)
  • ANAB 364.4K
  • ASIC 135.7K
  • Earning Date
  • ANAB 11-04-2025
  • ASIC 10-22-2025
  • Dividend Yield
  • ANAB N/A
  • ASIC N/A
  • EPS Growth
  • ANAB N/A
  • ASIC N/A
  • EPS
  • ANAB N/A
  • ASIC 0.17
  • Revenue
  • ANAB $169,467,000.00
  • ASIC $405,657,000.00
  • Revenue This Year
  • ANAB $37.52
  • ASIC $16.14
  • Revenue Next Year
  • ANAB N/A
  • ASIC $47.06
  • P/E Ratio
  • ANAB N/A
  • ASIC $108.29
  • Revenue Growth
  • ANAB 196.42
  • ASIC 42.48
  • 52 Week Low
  • ANAB $12.21
  • ASIC $16.35
  • 52 Week High
  • ANAB $40.96
  • ASIC $25.30
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 72.78
  • ASIC N/A
  • Support Level
  • ANAB $34.22
  • ASIC N/A
  • Resistance Level
  • ANAB $37.08
  • ASIC N/A
  • Average True Range (ATR)
  • ANAB 2.03
  • ASIC 0.00
  • MACD
  • ANAB -0.18
  • ASIC 0.00
  • Stochastic Oscillator
  • ANAB 68.07
  • ASIC 0.00

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About ASIC Ategrity Specialty Insurance Company Holdings Common Stock

Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.

Share on Social Networks: